Gubra today announced the launch of Gubra Ventures, a new business unit focused on creating independent biotechnology companies from high-quality scientific innovation. Zoë Johnson has been appointed Head of Gubra Ventures and will lead the identification, development, and early growth…
AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high solubility, and a favorable pharmacokinetic profile consistent with a long-acting peptide IND-enabling studies…
Gubra today announced the appointment of Thomas Langenickel, M.D., as Chief Medical and Development Officer (CMDO). Dr. Langenickel brings more than two decades of experience in big pharma and biotech, spanning drug discovery, translational medicine, and clinical development. In his…
Gubra A/S (“Gubra”) today announced a significant expansion of its laboratory and office facilities at DTU Science Park, located in immediate proximity to the company’s headquarters in Hørsholm, Denmark. The expansion provides a strong foundation for continued growth across both…
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in…
Gubra A/S (“Gubra”), a company specialized in peptide-based drug discovery, and Camurus AB (“Camurus”), an international, science-led biopharmaceutical company focused on developing and commercializing innovative, long-acting medicines today announce an exclusive collaboration and license agreement aimed at creating a long-acting…
· Favorable Phase I profile and encouraging weight loss signals of potential first-in-class triple agonist BI 3034701 supports further developmentGubra partner Boehringer Ingelheim today announced the advancement of BI 3034701, its long‑acting potential first-in-class triple‑agonist peptide, in development for the…
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in…
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in…
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in…